Showing 241 - 260 results of 23,032 for search '(( 16 b decrease ) OR ( 50 ((((nn decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 0.64s Refine Results
  1. 241
  2. 242
  3. 243
  4. 244
  5. 245
  6. 246

    Sensitivity analysis of 50:50 model. by Rachael Miller Neilan (10678614)

    Published 2021
    “…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”
  7. 247
  8. 248

    Table_4_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

    Published 2020
    “…</p><p>Results: The median age of onset was 60.3 years, and 30 (60.0%) of 50 patients were male. Abdominal pain was the most common symptom, followed by incidentaloma and B symptoms. …”
  9. 249

    Table_1_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

    Published 2020
    “…</p><p>Results: The median age of onset was 60.3 years, and 30 (60.0%) of 50 patients were male. Abdominal pain was the most common symptom, followed by incidentaloma and B symptoms. …”
  10. 250

    Table_2_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

    Published 2020
    “…</p><p>Results: The median age of onset was 60.3 years, and 30 (60.0%) of 50 patients were male. Abdominal pain was the most common symptom, followed by incidentaloma and B symptoms. …”
  11. 251

    The decreasing rates of V<sub>p</sub> with temperature. by Nazlı Tunar Özcan (14833635)

    Published 2023
    “…The V<sub>p</sub> and the σ<sub>t</sub> of Çankırı rock salt decrease with increasing temperatures of samples whereas the σ<sub>c</sub> increases. …”
  12. 252
  13. 253
  14. 254
  15. 255
  16. 256

    Expanding Three-Coordinate Gold(I) Anticancer Agent Chemical Space by Charles E. Greif (21728091)

    Published 2025
    “…The complexes demonstrated submicromolar cytotoxic activity against human breast cancer cells MDA-MB-231 or MDA-MB-468 with IC<sub>50</sub>’s in the range of 0.4–5.0 μM. Complex <b>2e</b> shows high potency in vitro and decreases 3D-breast cancer mammosphere viability. …”
  17. 257
  18. 258
  19. 259
  20. 260